Mineral chaperones: A role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification

Journal of Molecular Medicine

Volumn 86, Issue 4, 2008, Pages 379-389

  Jahnen Dechent, Willi ^a   Schäfer, Cora ^a   Ketteler, Markus ^b   McKee, Marc D ^c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b KLINIKUM COBURG   (Germany)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Atherosclerosis; CKD MBD; Fetuin A; Macrophage; Mineral Homeostasis; Osteopontin; Pathologic calcification; Phagocytosis; Vascular calcification

Indexed keywords

ALKALINE PHOSPHATASE; BINDING PROTEIN; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM PHOSPHATE; CALCIUM SALT; CHAPERONE; COMET; EDETIC ACID; ETIDRONIC ACID; FETUIN A; GLYCOPHORIN A; HIGH DENSITY LIPOPROTEIN; IBANDRONIC ACID; LIPID; LOW DENSITY LIPOPROTEIN; MINERAL; NUTRACEUTICAL; OSTEOPONTIN; PAMIDRONIC ACID; PHOSPHATE; SODIUM THIOSULFATE; TETRACYCLINE; UNCLASSIFIED DRUG;

AMYLOIDOSIS; BLOOD VESSEL CALCIFICATION; BONE MINERALIZATION; CALCIFICATION; CALCINOSIS; CALCIUM BLOOD LEVEL; DIET THERAPY; EVENING DOSAGE; HEMODIALYSIS PATIENT; HIGH RISK POPULATION; HUMAN; KIDNEY CALCIFICATION; KIDNEY FAILURE; LIPID BLOOD LEVEL; MACROPHAGE; NONHUMAN; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SCINTIGRAPHY; SCLERODERMA; SOFT TISSUE; TISSUE INJURY;

ANIMALS; BLOOD PROTEINS; BONE AND BONES; CALCINOSIS; HUMANS; KIDNEY FAILURE, CHRONIC; MACROPHAGES; MINERALS; OSTEOPONTIN;

EID: 42449125305     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-007-0294-y     Document Type: Review

References (70)

1. London GM, Marchais SJ, Guerin AP, Metivier F (2005) Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 14:525-531
2. Price PA, Thomas GR, Pardini AW, Figueira WF, Caputo JM, Williamson MK (2002) Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats. J Biol Chem 277:3926-3934
3. Schinke T, Amendt C, Trindl A, Pöschke O, Müller-Esterl W, Jahnen-Dechent W (1996) The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 271:20789-20796
4. Jahnen-Dechent W, Schäfer C, Heiss A, Grötzinger J (2001) Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin. Z Kardiol 90(Suppl 3):47-56
5. Schäfer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Müller-Esterl W, Schinke T, Jahnen-Dechent W (2003) The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112:357-366
6. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J (2003) Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361:827-833
7. Heiss A, DuChesne A, Denecke B, Grötzinger J, Yamamoto K, Renné T, Jahnen-Dechent W (2003) Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 278:13333-13341
8. Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, Jahnen-Dechent W, Shanahan CM (2005) Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 16:2920-2930
9. Westenfeld R, Schäfer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, Jahnen-Dechent W (2007) Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant 22:1537-1546
10. Heiss A, Jahnen-Dechent W, Endo H, Schwahn D (2007) Structural dynamics of a colloidal protein - mineral complex bestowing on calcium phosphate a high solubility in biological fluids. Biointerphases 2:16-20
11. Schäfer C, Jahnen-Dechent W (2007) The biological and cellular role of fetuin family proteins in biomineralization. In: Baeuerlein E, Behrens P, Epple M (eds) Handbook of biomineralization. Wiley VCH, Weinheim
12. Price PA, Nguyen TM, Williamson MK (2003) Biochemical characterization of the serum fetuin-mineral complex. J Biol Chem 278:22153-22160
13. Price PA, Lim JE (2003) The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 278:22144-22152
14. Jahnen-Dechent W (2004) Lot's wife's problem revisted: how we prevent pathological calcification. In: Baeuerlein E (ed) Biomineralization progress in biology, molecular biology and application. Wiley-VCH, Weinheim
15. Berthold LD, Froelich JJ, Barth P, Pogarell O, Klose KJ (1999) Pulmonary, nodular cavernous, calcifying form of amyloidosis. Radiologe 39:323-326
16. Ghadially FN (2001) As you like it, Part 3: a critique and historical review of calcification as seen with the electron microscope. Ultrastruct Pathol 25:243-267
17. Fine A, Zacharias J (2002) Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy. Kidney Int 61:2210-2217
18. Blumenthal NC (1989) Mechanisms of inhibition of calcification. Clin Orthop 247:279-289
19. Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G (2005) Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 19:1093-1104
20. Murshed M, Schinke T, McKee MD, Karsenty G (2004) Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 165:625-630
21. Nesbitt SA, Horton MA (1997) Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 276:266-269
22. Stenbeck G, Horton MA (2004) Endocytic trafficking in actively resorbing osteoclasts. J Cell Sci 117:827-836
23. Salo J, Lehenkari P, Mulari M, Metsikko K, Vaananen HK (1997) Removal of osteoclast bone resorption products by transcytosis. Science 276:270-273
24. Whyte MP (1994) Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr Rev 15:439-461
25. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millan JL (2004) Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 164:1199-1209
26. Anderson HC, Garimella R, Tague SE (2005) The role of matrix vesicles in growth plate development and biomineralization. Front Biosci 10:822-837
27. Shanahan CM (2005) Mechanisms of vascular calcification in renal disease. Clin Nephrol 63:146-157
28. Cisar JO, Xu DQ, Thompson J, Swaim W, Hu L, Kopecko DJ (2000) An alternative interpretation of nanobacteria-induced biomineralization. Proc Natl Acad Sci U S A 97:11511-11515
29. Benzerara K, Miller VM, Barell G, Kumar V, Miot J, Brown GE Jr, Lieske JC (2006) Search for microbial signatures within human and microbial calcifications using soft x-ray spectromicroscopy. J Investig Med 54:367-379
30. Vali H, McKee MD, Ciftcioglu N, Sears SK, Plows FL, Chevet E, Ghiabi P, Plavsic M, Kajander EO, Zare RN (2001) Nanoforms: A new type of protein-associated mineralization. Geochim Cosmochim Acta 65:63-74
31. Kajander EO, Ciftcioglu N (1998) Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc Natl Acad Sci U S A 95:8274-8279
32. Gupta HS, Seto J, Wagermaier W, Zaslansky P, Boesecke P, Fratzl P (2006) Cooperative deformation of mineral and collagen in bone at the nanoscale. Proc Natl Acad Sci U S A 103:17741-17746
33. Triffitt JT, Gebauer U, Ashton BA, Owen ME, Reynolds JJ (1976) Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature 262:226-227
34. McKee MD, Farach-Carson MC, Butler WT, Hauschka PV, Nanci A (1993) Ultrastructural immunolocalization of noncollagenous (osteopontin and osteocalcin) and plasma (albumin and alpha 2HS-glycoprotein) proteins in rat bone. J Bone Miner Res 8:485-496
35. Moe SM, Reslerova M, Ketteler M, O'Neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX (2005) Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67:2295-2304
36. Villanueva EV, Wasiak J, Petherick ES (2003) Percutaneous transluminal rotational atherectomy for coronary artery disease. Cochrane Database Syst Rev 4:CD003334
37. Hankermeyer CR, Ohashi KL, Delaney DC, Ross J, Constantz BR (2002) Dissolution rates of carbonated hydroxyapatite in hydrochloric acid. Biomaterials 23:743-750
38. Ohashi KL, Culkar J, Riebman JB, Estes M, Constantz BR, Yoganathan AP (2004) Hemodynamic characterization of calcified stenotic human aortic valves before and after treatment with a novel aortic valve repair system. J Heart Valve Dis 13:582-592 (discussion 592)
39. Slatopolsky E, Brown A, Dusso A (2005) Calcium, phosphorus and vitamin D disorders in uremia. Contrib Nephrol 149:261-271
40. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P (2007) Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2:898-905
41. Guerra G, Shah RC, Ross EA (2005) Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant 20:1260-1262
42. Cicone JS, Petronis JB, Embert CD, Spector DA (2004) Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 43:1104-1108
43. Yatzidis H (1985) Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol 23:63-67
44. Shiraishi N, Kitamura K, Miyoshi T, Adachi M, Kohda Y, Nonoguchi H, Misumi S, Maekawa Y, Murayama T, Tomita M, Tomita K (2006) Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 48:151-154
45. Monney P, Nguyen QV, Perroud H, Descombes E (2004) Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 19:2130-2132
46. Persy V, De Broe M, Ketteler M (2006) Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels? Kidney Int 70:1537-1538
47. van der Sluis IM, Boot AM, Vernooij M, Meradji M, Kroon AA (2006) Idiopathic infantile arterial calcification: clinical presentation, therapy and long-term follow-up. Eur J Pediatr 165:590-593
48. Maniscalco BS, Taylor KA (2004) Calcification in coronary artery disease can be reversed by EDTA-tetracycline long-term chemotherapy. Pathophysiology 11:95-101
49. Silay MS, Miroglu C (2007) The risk of urolithiasis recurrence may be reduced with anti-nanobacterial therapy. Med Hypotheses 68:1348-1350
50. Essalihi R, Dao HH, Gilbert LA, Bouvet C, Semerjian Y, McKee MD, Moreau P (2005) Regression of medial elastocalcinosis in rat aorta: a new vascular function for carbonic anhydrase. Circulation 112:1628-1635
51. Essalihi R, Zandvliet ML, Moreau S, Gilbert LA, Bouvet C, Lenoel C, Nekka F, McKee MD, Moreau P (2007) Distinct effects of amlodipine treatment on vascular elastocalcinosis and stiffness in a rat model of isolated systolic hypertension. J Hypertens 25:1879-1886
52. Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, DeMey JG, Vermeer C (2007) Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 109:2823-2831
53. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, Karsenty G, Giachelli CM (2002) Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 196:1047-1055
54. Gravallese EM (2003) Osteopontin: a bridge between bone and the immune system. J Clin Invest 112:147-149
55. Singh M, Ananthula S, Milhorn DM, Krishnaswamy G, Singh K (2007) Osteopontin: a novel inflammatory mediator of cardiovascular disease. Front Biosci 12:214-221
56. McKee MD, Nanci A (1996) Secretion of Osteopontin by macrophages and its accumulation at tissue surfaces during wound healing in mineralized tissues: a potential requirement for macrophage adhesion and phagocytosis. Anat Rec 245:394-409
57. Ohri R, Tung E, Rajachar R, Giachelli CM (2005) Mitigation of ectopic calcification in osteopontin-deficient mice by exogenous osteopontin. Calcif Tissue Int 76:307-315
58. Pampena DA, Robertson KA, Litvinova O, Lajoie G, Goldberg HA, Hunter GK (2004) Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem J 378:1083-1087
59. Hoyer JR, Asplin JR, Otvos L (2001) Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 60:77-82
60. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770-1773
61. Savill J, Fadok V (2000) Corpse clearance defines the meaning of cell death. Nature 407:784-788
62. Gregory CD, Devitt A (2004) The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? Immunology 113:1-14
63. Hoffmeister KM, Felbinger TW, Falet H, Denis CV, Bergmeier W, Mayadas TN, von Andrian UH, Wagner DD, Stossel TP, Hartwig JH (2003) The clearance mechanism of chilled blood platelets. Cell 112:87-97
64. Lee L (1962) Reticuloendothelial clearance of circulating fibrin in the pathogenesis of the generalized Shwartzman reaction. J Exp Med 115:1065-1082
65. Owens DE 3rd, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93-102
66. Saini HK, Xu YJ, Arneja AS, Tappia PS, Dhalla NS (2005) Pharmacological basis of different targets for the treatment of atherosclerosis. J Cell Mol Med 9:818-839
67. Blank M, Nur I, Toub O, Maor A, Shoenfeld Y (2005) Toward molecular targeting with specific intravenous immunoglobulin preparation. Clin Rev Allergy Immunol 29:213-217
68. Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ, van Snick J, Kuiper J (2005) Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 112:1054-1062
69. Stoll G, Bendszus M (2006) Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 37:1923-1932
70. Nadra I, Mason JC, Philippidis P, Florey O, Smythe CD, McCarthy GM, Landis RC, Haskard DO (2005) Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification? Circ Res 96:1248-1256